iShares Nasdaq Biotechnology ETF (IBB)
118.24
-0.02 -0.02%
NASDAQ
Jul 23, 13:03
Delayed 2m
USD
IBB Key Stats
| Net Asset Value | Upgrade |
| Discount or Premium to NAV | Upgrade |
| Turnover Ratio | Upgrade |
| 1 Year Fund Level Flows | Upgrade |
View All IBB News
IBB News
-
WireHeadlineTime (ET)
-
MT Newswires07/23 09:13
-
MT Newswires07/20 13:41
-
MT Newswires07/20 09:20
-
MT Newswires07/19 13:51
-
SA Breaking News07/19 11:10
-
MT Newswires07/19 09:26
-
Yahoo07/19 08:00
-
SA Breaking News07/18 15:08
-
MT Newswires07/18 13:51
-
MT Newswires07/18 09:19
IBB Performance
| Total Return (Price) | Total Return (NAV) | Cat. Total Return (NAV) | % Rank in Cat. (NAV) | |
|---|---|---|---|---|
| 1M | 3.98% | 3.95% | 1.32% | 5 |
| 3M | 12.83% | 12.75% | 10.21% | 19 |
| 6M | 5.74% | 5.65% | 6.72% | 48 |
| YTD | 10.92% | 10.89% | 13.13% | 50 |
| 1Y | 10.19% | 10.13% | 16.16% | 61 |
| 3Y | -3.55% | -3.55% | 4.09% | 90 |
| 5Y | 12.91% | 12.89% | 14.10% | 60 |
| 10Y | 15.95% | 15.97% | 13.92% | 22 |
IBB Asset Allocation
| Type | % Net | % Long | % Short |
|---|---|---|---|
| Cash | 0.02% | 0.04% | 0.02% |
| Stock | 99.98% | 99.98% | 0.00% |
| Bond | 0.00% | 0.00% | 0.00% |
| Convertible | 0.00% | 0.00% | 0.00% |
| Preferred | 0.00% | 0.00% | 0.00% |
| Other | 0.00% | 0.00% | 0.00% |
IBB Region Exposure
| Americas | 97.46% |
| North America | 97.46% |
| Latin America | 0.00% |
| Greater Europe | 2.14% |
| United Kingdom | 0.67% |
| Europe Developed | 1.44% |
| Europe Emerging | 0.00% |
| Africa/Middle East | 0.03% |
| Greater Asia | 0.41% |
| Japan | 0.00% |
| Australasia | 0.00% |
| Asia Developed | 0.00% |
| Asia Emerging | 0.41% |
| Market Classification | |
| % Developed Markets | 99.59% |
| % Emerging Markets | 0.41% |
IBB Stock Sector Exposure
| Basic Materials | 0.00% |
| Communication Services | 0.00% |
| Consumer Cyclical | 0.00% |
| Consumer Defensive | 0.07% |
| Energy | 0.00% |
| Financial Services | 0.00% |
| Healthcare | 99.89% |
| Industrials | 0.00% |
| Real Estate | 0.00% |
| Technology | 0.04% |
| Utilities | 0.00% |
IBB Stock Market Capitalization
| Giant | 16.25% |
| Large | 40.79% |
| Medium | 22.60% |
| Small | 17.25% |
| Micro | 3.10% |
IBB Stock Style Exposure
| Large Cap Value | 20.76% |
| Large Cap Blend | 17.00% |
| Large Cap Growth | 21.64% |
| Mid Cap Value | 0.00% |
| Mid Cap Blend | 3.37% |
| Mid Cap Growth | 18.19% |
| Small Cap Value | 1.30% |
| Small Cap Blend | 4.60% |
| Small Cap Growth | 13.13% |
View More Holdings
As of July 18, 2018
IBB Top 10 Holdings
| Symbol | Name | % Weight | Price | % Chg |
|---|---|---|---|---|
| BIIB | Biogen Inc | 8.93% | 357.91 | -0.22% |
| GILD | Gilead Sciences Inc | 8.38% | 77.43 | +0.08% |
| AMGN | Amgen Inc | 7.86% | 190.15 | -0.18% |
| CELG | Celgene Corp | 7.38% | 85.11 | +0.01% |
| ILMN | Illumina Inc | 5.36% | 311.76 | +0.20% |
| REGN | Regeneron Pharmaceuticals Inc | 4.46% | 365.86 | -0.34% |
| VRTX | Vertex Pharmaceuticals Inc | 4.30% | 176.85 | -0.31% |
| ALXN | Alexion Pharmaceuticals Inc | 3.66% | 133.78 | -1.02% |
| MYL | Mylan NV | 2.25% | 35.73 | +0.56% |
| BMRN | Biomarin Pharmaceutical Inc | 2.20% | 101.68 | -0.22% |
Advertisement
IBB One Page Reports
- One Page Report Download
IBB Basic Info
| Style | |
|---|---|
| Equity Style | Large Cap/Growth |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Prospectus Objective | Specialty - Technology |
| Fund Owner Firm Name | iShares |
| Benchmark Index | |
|---|---|
NASDAQ Biotechnology TR USD |
100.0% |
IBB Manager Info
| Name | Tenure |
|---|---|
| Alan Mason | 2.21 yrs |
| Diane Hsiung | 10.50 yrs |
| Greg Savage | 10.50 yrs |
| Jennifer Hsui | 5.92 yrs |
IBB Net Fund Flows
| 1M | 37.43M |
| 3M | -387.32M |
| 6M | -1.321B |
| YTD | -1.321B |
| 1Y | -1.270B |
| 3Y | 671.72M |
| 5Y | 2.796B |
| 10Y | 3.284B |
IBB Risk Info
| Beta (5Y) | 1.290 |
| Max Drawdown (All) | 62.85% |
| Historical Sharpe (10Y) | 0.8699 |
| Historical Sortino (All) | 0.5726 |
| 30-Day Rolling Volatility | 18.15% |
| Daily Value at Risk (VaR) 1% (All) | 4.84% |
| Monthly Value at Risk (VaR) 1% (All) | 19.46% |
IBB Fundamentals
| Dividend Yield TTM (7-23-18) | 0.27% |
| SEC Yield (4-30-18) | 0.13% |
| Weighted Average PE Ratio | 29.21 |
| Weighted Average Price to Sales Ratio | 6.149 |
| Weighted Average Price to Book Ratio | 5.179 |
| Weighted Median ROE | 2.76% |
| Weighted Median ROA | -5.25% |
| Forecasted Dividend Yield | 0.58% |
| Forecasted PE Ratio | 15.25 |
| Forecasted Price to Sales Ratio | 4.977 |
| Forecasted Price to Book Ratio | 3.779 |
| Number of Holdings | 194 |
IBB Growth Estimates
| Forecasted 5 Yr Earnings Growth | 13.63% |
| Forecasted Book Value Growth | 13.91% |
| Forecasted Cash Flow Growth | 2.92% |
| Forecasted Earnings Growth | -12.71% |
| Forecasted Revenue Growth | 11.39% |
IBB Attributes
| Key Dates | |
|---|---|
| Inception Date | 2/5/2001 |
| Termination Date | |
| Last Annual Report Date | 3/31/2018 |
| Last Prospectus Date | 6/26/2018 |
| Attributes | |
| Exchange Traded Share | Yes |
| Exchange Traded Note | No |
| Enhanced Index Fund | No |
| Index Fund | Yes |
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | Yes |
| Socially Responsible Fund | No |
| General Availability | |
| Available for Insurance Product | No |
| Available for Retirement Plan | No |
| Available for RRSP | No |
IBB Excel Add-In Codes
- Name: =YCI("IBB","name")
- Broad Asset Class: =YCI("IBB", "broad_asset_class")
- Broad Category: =YCI("IBB", "broad_category_group")
- Prospectus Objective: =YCI("IBB", "prospectus_objective")
To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.
Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.
Advertisement
